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Background: Indoleamine 2,3-dioxygenase (IDO) is an enzyme with immune-suppressive properties that is commonly
exploited by tumors to evade immune destruction. Anti-tumor T cell responses can be initiated in solid tumors, but are
immediately suppressed by compensatory upregulation of immunological checkpoints, including IDO. In addition
to these known effects on the adaptive immune system, we previously showed widespread, T cell-dependent
complement deposition during allogeneic fetal rejection upon maternal treatment with IDO-blockade. We
hypothesized that IDO protects glioblastoma from the full effects of chemo-radiation therapy by preventing
vascular activation and complement-dependent tumor destruction.
Methods: To test this hypothesis, we utilized a syngeneic orthotopic glioblastoma model in which GL261
glioblastoma tumor cells were stereotactically implanted into the right frontal lobes of syngeneic mice. These
mice were treated with IDO-blocking drugs in combination with chemotherapy and radiation therapy.
Results: Pharmacologic inhibition of IDO synergized with chemo-radiation therapy to prolong survival in mice
bearing intracranial glioblastoma tumors. We now show that pharmacologic or genetic inhibition of IDO allowed
chemo-radiation to trigger widespread complement deposition at sites of tumor growth. Chemotherapy
treatment alone resulted in collections of perivascular leukocytes within tumors, but no complement deposition.
Adding IDO-blockade led to upregulation of VCAM-1 on vascular endothelium within the tumor microenvironment,
and further adding radiation in the presence of IDO-blockade led to widespread deposition of complement. Mice
genetically deficient in complement component C3 lost all of the synergistic effects of IDO-blockade on
chemo-radiation-induced survival.
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Conclusions: Together these findings identify a novel mechanistic link between IDO and complement, and
implicate complement as a major downstream effector mechanism for the beneficial effect of IDO-blockade after
chemo-radiation therapy. We speculate that this represents a fundamental pathway by which the tumor regulates
intratumoral vascular activation and protects itself from immune-mediated tumor destruction.
Keywords: IDO, Indoleamine, Complement, Tumor, Immunotherapy, Chemotherapy, Radiation therapy,
Indoximod, Glioblastoma, NLG919Background
Immune responses to established tumors, and particularly
brain tumors, are commonly ineffective in controlling
tumor progression [1,2]. Nonetheless, vaccines against
glioblastoma-specific antigens have resulted in im-
proved survival in clinical trials, and chemotherapy ap-
pears to enhance this beneficial effect [3,4]. Emerging
evidence indicates that brain tumors are not irreversibly
“immune-privileged,” but rather employ a number of
regulatory mechanisms to prevent immune-mediated
tumor destruction [2,5]. Identifying and therapeutically
targeting these poorly understood immune regulatory
mechanisms could enable induction of protective, en-
dogenous anti-tumor immunity.
Indoleamine 2,3-dioxygenase (IDO), an enzyme with
immunosuppressive properties, has been detected in a
wide variety of human tumors, including glioblastoma,
and in tumor draining lymph nodes [6-8]. High tumor
expression of IDO is an independent risk factor for poor
outcome in a variety of human cancers, including glio-
blastoma, and orthotopic syngeneic GL261 tumors grown
in C57BL/6 mice were shown in 2012 to exhibit an IDO-
rich tumor microenvironment that protects tumors from
T cell attack [7].
Mechanistically, IDO has been shown to suppress T cell
responses and to promote activation of regulatory T cells
(Treg cells) in settings as diverse as mucosal tolerance,
pregnancy, chronic infection and organ transplantation
[reviewed in [9]]. In addition to these known effects on
the adaptive immune system, we previously showed wide-
spread, T cell-dependent complement deposition during
allogeneic fetal rejection upon maternal treatment with
IDO-blockade [10]. IDO-dependent generation of the bio-
active tryptophan metabolite kynurenine is a potent vaso-
dilator [11] that appears to be critically important in
preventing tissue rejection in one allogeneic heart graft
model [12,13]. Whether and how these mechanisms im-
pact tumor growth are unclear, but the strong association
between IDO expression and progressive tumor growth
has led to ongoing early-phase trials to test whether
targeting IDO has clinical efficacy.
In preclinical models, IDO-inhibitors were shown to
have synergistic effects when administered with multipleclasses of chemotherapy agents and radiation [14,15]. Early-
phase clinical trials combining standard chemotherapy
with IDO-inhibitor drugs, such as 1-methyl-D-tryptophan
(D-1MT, indoximod) and NLG919, for treatment of refrac-
tory solid tumors are in progress. Such approaches have
not been previously attempted for brain tumors, and spe-
cific mechanisms through which IDO regulates tumor
progression under these conditions are not known. Based
on previously documented effects of radiation on inflam-
mation and vascular activation [1,16] and evidence that
IDO-blockade has some effect on tumor therapy [14,15],
we tested the hypothesis that the IDO protects glio-
blastoma from the full effects of chemo-radiation therapy
by preventing vascular activation and complement-
dependent tumor destruction.
Results
IDO-blockade synergizes with standard chemo-radiation
therapy to enhance survival in mice with glioblastoma
Clinically, glioblastoma tumors are treated with surgi-
cal resection, followed by temozolomide (TMZ)-based
chemotherapy plus local radiation. IDO-blockade has
been shown to enhance the effects of both chemother-
apy and radiation [14]. We tested the hypothesis that
blocking IDO synergizes with TMZ plus radiation therapy
(RT) to enhance survival in a murine model of glio-
blastoma. We employed the mouse glioblastoma cell
line GL261 which becomes a highly aggressive tumor
with short survival time, so treatment was focused on a
single cycle of therapy, and a synergistic effect was de-
fined as prolongation of survival relative to controls.
Seven days after injecting GL261 tumors, we treated
recipients with or without the prototypical IDO-
inhibitor compound, racemic 1-methyl-DL-tryptophan
[17] (DL-1MT, 4 mg/mL in drinking water), followed
by a single dose of TMZ (100 mg/kg) on day 9 and a
single fraction of RT (500 cGy total-body irradiation)
on day 10 (Figure 1A). Untreated mice reproducibly
died after approximately 3 weeks of tumor growth
(Additional file 1: Figure S1, range 18–24 days). Treat-
ment with TMZ + RT alone improved overall survival
relative to untreated mice (Figure 1A and B), adding
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Figure 1 IDO-blockade synergizes with chemo-radiation therapy. Orthotopic GL261 glioblastoma tumors were implanted stereotactically
into the right frontal lobes of syngeneic C57BL/6 host mice. Kaplan-Meier survival plots are shown, comparing mice treated with: A, temozolomide
plus radiation (TMZ+ RT) and with or without IDO-blockade using DL-1MT; B, TMZ + RT and with or without IDO-blockade using NLG919 or D-1MT;
C, cyclophosphamide plus RT (CPM+ RT) and with or without DL-1MT; or D, with CPM + RT plus either D-1MT or DL-1MT. IDO-blocking drugs (DL-1MT,
4 mg/mL; NLG919, 6 mg/mL; or D-1MT, 4 mg/mL) were supplied in drinking water continuously starting at day 7 after tumor implantation;
chemotherapy (TMZ, 100 mg/kg, i.p.; or CPM, 100 mg/kg, i.p.) was given on day 9, and RT (500 cGy) was given on day 10. For reference, each
survival plot contains a cohort of untreated mice, and mice treated with IDO-blockade using DL-1MT alone are shown in A. Cohort sizes (n) are
indicated for each treatment group and represent pooled data from multiple experiments containing 1–3 mice from each group per experiment. n.s.,
not significant [vs. untreated mice (A); or DL-1MT vs. D-1MT (D)]; *, P < 0.001 (vs. untreated mice); **, P < 0.002 (vs. mice treated with chemo-radiation
alone), by log-rank test.
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we observed a further prolongation of median survival
by an additional 6.5 days (37.5 vs. 31 days) (Figure 1A).
This is similar to the effect-size previously described as
clinically significant in this glioblastoma model [18,19].
We also tested the effect of two IDO-inhibitor drugs
that are currently in phase I clinical trials, 1-methyl-D-
tryptophan (D-1MT) and NLG919. When combined
with TMZ + RT, we observed that both NLG919 and
D-1MT enhanced survival relative to mice treated with
TMZ + RT alone (Figure 1B). The effect of these drugs
was similar, as survival was not significantly different
between groups treated with NLG919 plus TMZ+ RT vs.
D-1MT plus TMZ+ RT.
Additional experiments in which we employed shield-
ing to target the radiation dose to the cranium of the
mice yielded results essentially identical to total-body
irradiation (Additional file 1: Figure S2). In other con-
trol experiments, we observed that IDO-blockade had
no survival-enhancing effect when combined with either
TMZ alone (no RT; Additional file 1: Figure S3A), or
RT alone (no chemotherapy; Additional file 1: Figure S3B).
Together, these data indicate synergistic interactions
among the three therapies when used together (IDO-
blockade, TMZ, and RT), and the protective effect for
the host was not influenced by the breadth of the radi-
ation field.
IDO-blockade synergizes with subtherapeutic
cyclophosphamide plus radiation therapy to enhance
survival
We also tested the ability of IDO-inhibitors to synergize
with a cyclophosphamide (CPM)-based chemo-radiation
regimen using the same glioblastoma model. CPM has
been used to treat glioblastoma in the clinic [20] and
has been widely studied in the context of immunother-
apy [14,21]. We used a dose (100 mg/kg) that exhibited
no therapeutic benefit as a single agent (Additional file 1:
Figure S3C) and did not prolong survival when added to
RT alone (Additional file 1: Figure S3B). However,
when we added DL-1MT to CPM + RT we observed
significantly prolonged survival compared to animals
treated with CPM + RT alone (Figure 1C). Substitutingthe D-isomer of 1MT for the racemic mixture yielded the
same results (Figure 1D). As with TMZ, IDO-blockade
with CPM alone had no effect on survival (Additional
file 1: Figure S3C). Thus, D-1MT and DL-1MT equiva-
lently enhanced survival of mice with GL261 tumors
treated with CPM+RT. In the subsequent experiments in
this report, the D- and DL- preparations of 1MT were
both used, and results were consistently equivalent.
IDO target protein is expressed by GL261 tumors in vivo
GL261 tumors have been shown by others to express
IDO protein in vivo, even in mice genetically deficient in
the IDO-1 isoform [7,22]. We performed immunohisto-
chemical staining on frozen sections of GL261 tumors
to detect the presence of IDO protein in our system.
We observed distinct patterns of IDO expression in
tumor cells, in perivascular areas within and adjacent to
tumors, and in peritumoral cells with astrocytic morph-
ology (Additional file 1: Figure S4A). GL261 tumors were
also found to express the IDO-2 isoform after 18 days of
growth in either wild-type (WT) or IDO1-deficient host
mice (Additional file 1: Figure S5). Because survival was
improved when IDO-blockade was added to chemo-
radiation therapy, we next analyzed GL261 tumors from
treated host mice. We found that treatment of host mice
with TMZ, TMZ+ RT, or CPM+ RT did not affect IDO
target protein expression (Additional file 1: Figure S4B).
Chemotherapy alone promotes perivascular accumulation
of bone marrow-derived leukocyte cell populations within
tumors
The above studies show that the protective effect of IDO-
blockade requires both radiation and chemotherapy. To
begin to dissect out the mechanisms through which each
component of the therapeutic regimen contributed to
the improved outcome, and to test the hypothesis that
TMZ activates anti-tumor immunity and facilitates cel-
lular infiltration into tumor parenchyma, we examined
the brains from glioma-bearing mice treated with TMZ
alone (Figure 2). For these studies, we chose a modest
dose of TMZ (25 mg/kg) so that the peripheral leukocyte
populations would not be reduced and the effects on
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Figure 2 Bone marrow-derived leukocytes aggregate around tumor blood vessels after chemotherapy treatment alone. GL261 tumors
from WT host mice were harvested 16 – 20 days after implantation, and: A, at 3, 5, or 7 days after a single low-dose temozolomide injection
(25 mg/kg, i.p.) or B, from untreated mice. Tumors were frozen for immunohistochemical analysis of bone marrow-derived CD45-expressing
leukocytes (red) and endothelial cells (CD31, green). Nuclei were counterstained with Hoechst (blue). Representative photomicrographs of tumors
(A and B) and contralateral brain (A, lower panels) are shown. Original magnification, ×400; Scale bars, 25 μm. C, quantitative analysis was
performed to determine the frequency of perivascular leukocyte cuffs per 100 vessels within tumors (white bars) and in contralateral brain (black
bars) as a control. Photomicrographs were obtained in a grid pattern at magnification ×200 and analyzed for cuff frequency. Cuffs were counted
if they were circumferential and at least 3 cells thick. For each mouse, at least 90 CD31-positive vessels from at least six 200X fields were analyzed
for perivascular cuffs. Data are presented as mean ± SEM of 3 mice per time point, from 3 independent experiments. *, P < 0.0003, by ANOVA with
Kruskal-Wallis test.
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sections of brains harvested from glioma-bearing mice
3, 5, or 7 days after TMZ, using CD31 as a marker for
vascular endothelium and CD45 as a marker for leuko-
cytes derived from bone marrow.
Unexpectedly, instead of parenchymal infiltration of
immune cells after chemotherapy treatment, we observed
perivascular collections of CD45-positive leukocytes, as
early as 3 days after chemotherapy treatment, which
progressively increased over time (Figure 2A and C). In
contrast, no perivascular leukocyte cuffs were observed
in the contralateral (uninvolved) brain hemispheres.
This vascular focus of leukocyte aggregation was due to
chemotherapy, not the tumor itself, because only rare
small collections were found in control, untreated,
tumor-bearing mice (Figure 2B). Frequency analysis of
these tissues for perivascular cuffs (defining a cuff as atleast three layers of CD45-positive cells circumferen-
tially around a CD31-positive vessel) demonstrated a
significant increase in these large aggregates by day 7
after TMZ (Figure 2C). Finally, although TMZ can cause
peripheral leukopenia, perivascular leukocyte cuffs were
observed in tumors from mice treated with standard
doses of either TMZ (100 mg/kg) or CPM (100 mg/kg)
(Additional file 1: Figure S6).
The large perivascular cuffs from tumors harvested
7 days after TMZ (Additional file 1: Figure S7A) were
predominantly comprised of CD68+ macrophages (CD45+)
and microglia (CD45-lo), as well as substantial numbers
of CD4+ T cells (Additional file 1: Figure S7B). A large
proportion of the CD4 T cells co-stained for nuclear
Foxp3, indicating a Treg cell phenotype (Additional file 1:
Figure S7C). CD8 T cells were notably sparse in these
leukocyte collections (Additional file 1: Figure S7B).
Li et al. Journal for ImmunoTherapy of Cancer 2014, 2:21 Page 6 of 13
http://www.immunotherapyofcancer.org/content/2/1/21Treating tumor-bearing mice with high dose chemother-
apy plus RT caused the perivascular leukocyte cuffs and
vessels to become disorganized with downregulation of
endothelial CD31 expression (data not shown). Thus,
while a single modest dose of TMZ alone had only min-
imal effect on survival, the intervention initiated a process
of macrophage, microglia, and Treg cell aggregation at
vascular sites within the tumor.
Blocking IDO during chemotherapy enhances vascular
activation
We next tested the hypothesis that adding IDO-blockade
to temozolomide treatment activates tumor vessels
(Figure 3). We treated glioma-bearing mice using TMZ,
with or without 1MT. Tumors were harvested 5 days after
treatment and immunohistochemistry was used to stain
for vascular cell adhesion molecule-1 (VCAM-1) and
CD31. Vessels within tumors of mice treated with TMZ
alone expressed minimal VCAM-1. In contrast, when we
added 1MT to TMZ treatment, we observed scattered butB) TMZ +RT      







Figure 3 IDO-blockade drives vascular activation after chemotherapy
tumors were grown in WT host mice treated with TMZ (100 mg/kg, i.p.) an
water). Tumors were harvested 5 days after chemotherapy (18 days after im
cell adhesion molecule-1 (VCAM-1, red) on endothelial cells (CD31, green).
photomicrographs are shown of at least 3 mice per group, from at least 3
25 μm. B, GL261 tumors were grown in WT host mice treated with TMZ (1
drinking water). Tumors were harvested in formalin 5 days after chemother
architecture. Call-out panel highlights an area of local tumor necrosis. Data
independent experiments. Original magnification, ×200 (upper panels) andoften intense VCAM-1 staining co-localized to CD31 indi-
cative of endothelial cell upregulation (Figure 3A). In
addition, we found that adjacent brain tissue was com-
pletely uninvolved (Figure 3A). Thus, while adding 1MT
to TMZ treatment was completely ineffectual at enhan-
cing survival in mice with glioblastoma (Additional file 1:
Figure S3A), adding 1MT to TMZ selectively upregulated
VCAM-1 on endothelial cells in vessels within the tumor,
and this vascular activation was not found elsewhere in
the brain.
Because IDO-blockade had only provided synergistic
prolongation of survival when it was combined with both
chemotherapy and radiation, we next tested whether add-
ing 1MT to TMZ+ RT treatment altered the histological
features of the glioma. Figure 3B shows hematoxylin and
eosin (H&E) staining of formalin-fixed paraffin-embedded
tumors harvested from WT mice treated with TMZ + RT,
with or without 1MT. Control tumors treated with TMZ+
RT alone were viable with erythrocytes confined to in-
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areas of local tumor necrosis (Figure 3B). Similar effects
were seen using cyclophosphamide in place of TMZ
(data not shown).
IDO regulates complement deposition within the tumor
We knew from prior work that IDO-blockade caused
widespread complement deposition in the setting of allo-
geneic concepti being rejected after pregnant mice were
treated with IDO-inhibitor drugs [10]. To test whether
complement was an important mechanism in driving syn-
ergy between IDO-blockade and chemo-radiation therapy,
we treated glioma-bearing WT mice with TMZ+RT, with
or without either 1MT or NLG919. We assessed tumors
using immunohistochemistry to co-stain for complement
component C3 and CD31 (Figure 4).
We found that GL261 tumors from untreated mice
did not stain for C3, and tumors from mice treated with
TMZ + RT showed only scattered interstitial C3 staining
(Figure 4A). However, when we combined TMZ + RT
with IDO-blockade using either 1MT or NLG919, we ob-
served extensive and confluent C3 deposition (Figure 4B).
To test whether IDO was required for complement depos-
ition, we treated IDO-deficient mice with TMZ+RT. We
observed the same deposition of C3 in tumors from IDO-
deficient host mice treated with TMZ+RT as we found in
tumors from WT mice treated with IDO-blockade plus
TMZ + RT (Figure 4B). We also found that C3 accumu-
lation in tumors required the full combination of IDO-
blockade with chemo-radiation therapy, as comple-
ment deposition was not seen in mice treated with
IDO-blockade alone, IDO-blockade with TMZ (no RT),
or IDO-blockade with RT (no TMZ) (Additional file 1:
Figure S8). We also found that C3 deposition was
strictly confined to the tumor microenvironment, and
adjacent brain tissue was completely spared (Figure 4B).
Thus, host IDO activity regulated complement deposition
in glioblastoma tumors after chemo-radiation therapy, and
complement deposition was highly selective and confined
to the tumor itself.
Image analysis software was used to quantitate pho-
tomicrographs of tumors stained for complement C3.
Fluorescence-intensity histograms were generated for
quantitative analysis of mean fluorescence intensity
(MFI) and percent of downfield-gated (positive) pixels
(Figure 4C). Tumors from mice with inactive IDO, ei-
ther due to IDO-blockade or genetic IDO deficiency,
treated with TMZ + RT had significantly increased
complement C3 MFI (Figure 4D) and Percent Down-
field Pixels (Figure 4E) compared to controls. Taken
together, these data indicate that pharmacological
blockade or genetic ablation of IDO allows TMZ + RT
to trigger widespread C3 deposition in tumors consist-
ent with local activation of the complement cascade,which is not observed when WT hosts are treated with
TMZ + RT alone.
Complement is mechanistically required for the beneficial
effects of blocking IDO during chemo-radiation therapy
The preceding studies suggested that the extensive com-
plement deposition observed in tumors when IDO was
blocked represented the final effector stage of a multi-step
inflammatory process. To test this hypothesis, we per-
formed survival studies using tumor-bearing WT hosts or
host mice lacking complement component C3 (C3−/−).
We first verified that GL261 tumors grown in C3-deficient
host mice retain the ability to express IDO at the protein
level, using immunohistochemical staining (Additional
file 1: Figure S9). For survival experiments, mice with
GL261 tumors were treated with or without 1MT and
chemo-radiation therapy, as shown in Figure 5. When we
treated mice with chemo-radiation therapy alone (no IDO-
inhibitor), we observed a comparable enhancement in sur-
vival relative to untreated controls, irrespective of whether
the hosts were C3−/− or WT. Thus, C3 deficiency did
not alter the underlying growth kinetics of the tumor, or
the baseline response to chemo-radiation therapy.
As before, when we added 1MT to the treatment regi-
men, we observed the expected additional enhancement
in survival for WT host mice. In contrast, we found that
C3−/− host mice completely lost the beneficial survival
effect of blocking IDO, and their survival curves became
essentially identical with or without 1MT. Thus, the sur-
vival benefit provided by adding IDO-blockade to chemo-
radiation therapy was strictly dependent on the ability of
this combination to activate the complement system, and
was abrogated in C3−/− host mice.
Discussion
IDO protects tumors from anti-tumor immunity, although
this has been thought to occur by suppression of T cell
responses. We now show that blocking IDO results in
C3-dependent tumor destruction, uncovering an un-
anticipated link between IDO and complement. In the
absence of an IDO inhibitor (IDO activity intact), we
did not observe complement deposition within tumors,
regardless of whether RT was added to standard chemo-
therapy (Figure 4A and Additional file 1: Figure S8).
Blocking IDO during chemo-radiation therapy led to
widespread intratumoral deposition of C3 (Figure 4B),
and the beneficial effect of IDO-blockade on survival
was completely dependent on host C3 (Figure 5). To-
gether, these data support the conclusion that inhibition
of IDO unleashes local complement activation, which in
turn affects tumor growth. The novel role for host IDO in
controlling complement deposition in tumors and the key
role that complement plays in damaging tumors when
IDO is blocked have not been previously described.
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Figure 4 Inhibition or absence of IDO triggers widespread complement deposition in tumors after chemo-radiation therapy. GL261
tumors were grown in syngeneic host mice treated with or without IDO-blocking drugs (1MT, 4 mg/mL; or NLG919, 6 mg/mL) in drinking water
starting on day 14, plus TMZ (100 mg/kg, i.p.) on day 16 and RT (500 cGy) on day 17. Tumors were harvested on day 18 and frozen for
immunohistochemical analysis of complement component C3 deposition (red) endothelial cells (CD31, green), and nuclei (Hoechst, blue). A,
representative photomicrographs of control tumors from WT host mice, either untreated or treated with TMZ + RT. B, representative photomicrographs
of tumors and adjacent normal brain from WT host mice treated with either TMZ + RT + 1MT or TMZ + RT + NLG919; and from syngeneic IDO-deficient
host mice treated with TMZ + RT. Data are representative of at least 3 mice per group, from at least 3 independent experiments. Original magnification,
×400; Scale bars, 25 μm. C to E, quantitative analysis of complement deposition. Photomicrographs of tumors stained for complement C3 (red) were
obtained in a grid pattern at magnification ×400, and image analysis software was used to abstract fluorescence intensity histograms from each
photomicrograph for quantitative analysis. C, Representative photomicrographs and histograms are shown. Scale bars, 25 μm. Histograms are labeled
with mean fluorescence intensity (MFI) and the proportion of pixels occurring downfield from an arbitrarily-chosen negative threshold (channel
thirty-two). Comparisons of MFI (D) and Percent Downfield Pixels (E) are shown with means represented by a solid bar. For each experimental group,
at least 35 photomicrographs were analyzed from 3 separate mice pooled from 3 independent experiments. *, P < 0.02; **, P < 0.002; ***, P < 10−6
(vs. WT mice treated with TMZ+ RT), by ANOVA with Kruskal-Wallis test.
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require further study, we speculate that complement acti-
vation contributes to a vascular collapse in the tumor, withwidespread “watershed” necrosis of tumor tissue that pro-
longs survival of the host animal. Any necrotic tumor cell
death would occur in the context of IDO-blockade, and
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Figure 5 Complement is mechanistically required for IDO-blockade to synergize with chemo-radiation therapy. GL261 tumors were
grown in syngeneic WT (upper panel) or complement C3-deficient (lower panel) host mice. Kaplan-Meier survival plots are shown, comparing
mice treated with: A, temozolomide plus radiation (TMZ + RT) and with or without IDO-blockade using DL-1MT; or B, cyclophosphamide plus
radiation (CPM + RT) and with or without DL-1MT. DL-1MT (4 mg/mL) was supplied in drinking water continuously starting at day 7 after tumor
implantation; chemotherapy (TMZ, 100 mg/kg; or CPM, 100 mg/kg) was given on day 9, and RT (500 cGy) was given on day 10. For reference,
each survival plot contains a cohort of untreated host mice. Cohort sizes (n) are indicated for each treatment group and represent pooled data
from multiple experiments containing 1–3 mice from each group per experiment. *, P < 0.0001 (vs. mice treated with chemo-radiation alone); n.s.,
not significant (vs. mice treated with chemo-radiation alone), by log-rank test.
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immunity to mount a late-phase anti-tumor attack and
develop immunological memory. We propose a model
where each component of therapy (chemotherapy, IDO-
blockade, radiation) contributes to a progressive sequence
of biological consequences (Figure 6). We postulate that
IDO normally imposes immunological quiescence on ves-
sels in tumors, and even on the progressive perivascular
leukocyte cuffs that form after chemotherapy. When IDO
is blocked and tumors are further exposed to radiation,these may act together to sensitize the chemotherapy-
induced perivascular cuff to allow innate inflammation,
endothelial cell activation, widespread complement C3
deposition, and microangiopathic tumor destruction.
Tryptophan catabolism resulting in production of
immuno-active kynurenine compounds and local tryp-
tophan depletion can be mediated by either IDO or
tryptophan 2,3-dioxygenase (TDO). We cannot rule
out a contribution by TDO in these GL261 tumors,

















Figure 6 Proposed sequence of events. Recap of the proposed sequence of biological consequences of adding each component of therapy,
culminating in local tumor necrosis, widespread complement deposition, and enhanced survival when RT is added to chemotherapy and
IDO-blockade.
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been careful not to assume that inability to measure
bioactive kynurenines equates to their absence in the
relevant microenvironments during IDO-blocking treat-
ment. However, there is a clear biological effect of block-
ing IDO with 1MT, which does not inhibit TDO [23], and
of genetic IDO-1 deficiency (Figure 4B-E). In the short-
term, IDO activity is important in suppressing comple-
ment deposition, and TDO does not appear to compen-
sate for this when IDO is blocked during chemo-radiation
therapy. Although TDO may be a problem for long-term
host survival, which has clinical and therapeutic implica-
tions, the mechanistic question has been answered by
IDO-deficient host mice which do develop complement
deposition in tumors after chemo-radiation treatment.
Nonetheless, it would be desirable to develop dual-
specificity inhibitors for clinical application.
We used this model to study the short-term effects of
adding IDO-blocking drugs to a single cycle of chemo-
radiation therapy. The goal of any single cycle of chemo-
radiation therapy is for the tumor to be smaller before
the next cycle begins, and any human cancer patient
would be treated with multiple cycles to compound the
damage to the tumor. We speculate that, in our short-
term model, adding IDO-blockade damages the tumor
acutely via intensified inflammation and vasculitis, effect-
ively amplifying the chemotherapy/radiation dose.
An emerging theme in cancer immunotherapy is the
importance of vascular activation and targeting in medi-
ating certain forms of tumor regression. Previous work
in the B16 melanoma model has shown that despite
evidence of peripheral anti-tumor T cell responses, tumor-
specific vaccines are ineffective in causing tumor rejection,
even when combined with CTLA-4-blockade and de-
pletion of host Treg cells, until radiation is used to
drive vascular activation [1]. Additional data from this
model suggest that anti-tumor T cell responses are initi-
ated in solid tumors, but immediately suppressed by
compensatory upregulation of immunological checkpoints,including IDO [24]. Adoptive transfer of melanoma-
specific CD8 T cells engineered to express IL-12 was
found to cause tumor involution via collapse of tumor
stroma and vasculature [25]. IL-12 is known to promote
IFNγ secretion, which in turn can induce IDO expression
in myeloid cell subsets [reviewed in [5]]. Preliminary ex-
periments in our model show that the adaptive immune
system is necessary for the formation of perivascular
leukocyte collections after chemotherapy (unpublished
data). It is also known from previous work that T cell in-
teractions with antigen-presenting cells and/or endothelial
cells initiate alternative pathway-dependent complement
activation yielding local production of C3a and C5a
[26-28]. These anaphylatoxins signal through their re-
ceptors on T cells to promote effector T cell activation
and expansion [26,28] and inhibit the generation, func-
tion, and stability of Treg cells [29]. We propose that
IDO-blockade during inflammatory chemo-radiation
therapy drives a positive feedback loop between com-
plement activation/deposition and pre-primed tumor-
specific effector T cells, which activates and amplifies
both processes.
Conclusions
Based on the prominent connection between IDO and
complement in settings as diverse as pregnancy and
brain tumors, we propose that locally inhibiting the
pro-inflammatory complement pathway is a fundamental
mechanism by which IDO helps create immune tolerance.
From a translational perspective, our data suggest that
there is substantially more anti-tumor efficacy available
from conventional chemo-radiation treatments if they are
given in a setting in which IDO is blocked, thus allowing
them to trigger the beneficial contribution of the comple-
ment pathway. Additional studies will be required to de-
termine which components of the complement cascade
are key mediators of the downstream biological effects of
blocking IDO, which complement regulatory pathways are
induced or maintained by IDO expression, and whether
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activation.Methods
Mice, glioma cell line, and reagents
C57BL/6, B6.129-Ido1tm1Alm/J (IDO1-deficient), and
B6;129S4-C3tm1Crr/J (complement C3-deficient) mice
were purchased from the Jackson Laboratory. Animal
studies were approved by the Institutional Animal Care
and Use Committee of Georgia Regents University.
GL-261 cells were purchased from the National Institutes
of Health Tumor Repository (Frederick, MD) and cultured
in RPMI-1640 media supplemented with 10% fetal bovine
serum, 4 mM L-glutamine, 100 IU/mL penicillin, and
100 μg/mL streptomycin (Corning Cellgro). IDO-inhibitor
drugs 1-methyl-D-tryptophan (D-1MT, catalog no.
452483) and 1-methyl-L-tryptophan (L-1MT, catalog
no. 447439) were purchased from Sigma-Aldrich, and
NLG919 was a generous gift from Mario Mautino
(NewLink Genetics). Primary antibodies for immunohisto-
chemical studies were purchased from: Abcam [rabbit
anti-mouse CD31 polyclonal antibody (catalog no. ab
28364)], eBioscience [rat anti-mouse CD45 (clone 30-
F11)], AbD Serotec [rat anti-mouse VCAM-1 (clone
MVCAM A(429))], and Cedarlane [rat anti-mouse com-
plement C3 (clone RmC11H9, specific for native mouse
C3 and breakdown products C3b, iC3b, and C3dg)].
Secondary immunohistochemistry reagents labeled with
Alexa Fluor 488 or Cy3 were purchased from Jackson
ImmunoResearch Laboratories, Inc.Tumors and animal treatments
Mice were anesthetized with 4% isoflurane, and the sur-
gical plane of anesthesia was maintained with 2% isoflur-
ane in oxygen. Mice were immobilized in a stereotactic
frame (Stoelting Company) for tumor implantation.
Briefly, the skull was shaved and exposed with a 0.5 cm
skin incision. With antiseptic technique, 105 GL261 cells
(suspended in 3 μL RPMI-1640) were injected at the
following coordinates with respect to the bregma on
the right side (antero-posterior, −2 mm; medio-lateral,
2 mm; dorso-ventral, 3 mm). This placement reprodu-
cibly yielded tumor growth in a paracortical area of the
posterolateral right frontal lobe. Tumor-bearing mice
were treated with combinations of oral DL-1MT
(2 mg/mL D-1MT mixed with 2 mg/mL L-1MT) in
drinking water, D-1MT (4 mg/mL) in drinking water,
NLG919 (6 mg/mL) in drinking water, intraperitoneal
cyclophosphamide (Baxter), intraperitoneal temozolo-
mide (Merck), and/or total-body radiation (500 cGy
from a 137Cs source), as detailed in figure legends.
Mice were observed daily, and sacrificed when they
became ill or moribund, which defined the ethicalsurrogate endpoint as approved by our animal-use
committee.
Immunofluorescence staining
Tumor tissue was harvested, snap-frozen, and stored
at −80°C until 5 μm sections were cut for immunohis-
tochemical staining. Tissue sections were fixed with
ethanol and acetone (1:1). Nonspecific binding to tis-
sue was then blocked with normal mouse serum and
serum matched to the secondary reagent host species.
Sections were incubated with primary antibody followed
by fluorescence-labeled secondary reagents. Nuclear coun-
terstain was performed using Hoechst (catalog no. 14530,
Sigma-Aldrich). Fluorescent microscopy (Olympus AX70
upright compound microscope) with a SPOT digital cam-
era and software (SPOT Imaging Solutions) was used to
generate photomicrographs.
Quantitation of complement C3 staining
Photomicrographs of tumors stained for complement
C3 (red) were obtained in a grid pattern at magnifica-
tion ×400. Abobe Photoshop CS6 (Adobe Systems, Inc.)
image analysis software was used to transform photomicro-
graphs of complement C3-labeled tumors into fluorescence-
intensity histograms for quantitative analysis of MFI and
percent of downfield-gated (positive) pixels, defined as oc-
curring above an arbitrarily-chosen negative threshold
(above channel thirty-two). Histograms for reproduction
in Figure 4 were generated by FastStone Image Viewer
(FastStone Soft, 2013).
Statistics
Statistical analysis was performed using NCSS 2007
statistical software (NCSS, LLC.). For survival data,
Kaplan-Meier curves were analyzed by the log-rank
test. For frequency analysis of perivascular cuff and
quantitative analysis of complement C3 (MFI and Per-
cent Downfield Pixels), ANOVA with Kruskal-Wallis
test was used. Significance was defined as a P value less
than 0.05. Time to ethical surrogate endpoint was
treated as survival time for statistical analysis.
Additional file
Additional file 1: Figure S1. Survival time is highly reproducible in
untreated mice with intracranial GL261 tumors. Figure S2. Corporal
shielding during radiation therapy does not affect synergy between IDO-
blockade and chemo-radiation therapy. Figure S3. Neither chemotherapy
alone nor radiation therapy alone are sufficient to drive synergy with
IDO-blockade. Figure S4. IDO is expressed by GL261 tumors in vivo.
Figure S5. IDO-2 is expressed by GL261 tumors in vivo. Figure S6.
Perivascular leukocyte collections form around tumor blood vessels after
treatment with standard-dose chemotherapy. Figure S7. Macrophages,
microglia and regulatory CD4 T cells predominate in perivascular
leukocyte aggregates after chemotherapy. Figure S8. Complement
deposition does not occur without the combination of IDO-pathway
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by GL261 tumors grown in complement C3-deficient host mice.
Methods for supplemental figures.
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